[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prediabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prediabetes":61},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,129,0,25,[9,45,75,115,146,167,193,232,258,290,329,353,387,415,439,450,474,504,524,532,557,583,601,626,651],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053897","understanding-metabolism-and-inflammation-risks-for-diabetes-in-adolescents-100053897",false,"NCT06007404","Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents","The Role of Circulating Meta-Inflammatory Monocytes in Adolescent Insulin Resistance","Inclusion Criteria:\n\n* Between 14 and 18 years of age\n* Tanner stage 4 or 5 (mature adult stage of puberty)\n* Normal weight (BMI ≥ 5th percentile \\& \\\u003C 85th percentile), overweight (BMI \\> 86th percentile) \\& \\\u003C 94th percentile), obese weight (BMI percentile ≥ 95th percentile), and\u002For pre-diabetes (HbA1c \\> 5.7%)\n* For Type 2 Diabetes cohort, diagnosis of Type 2 Diabetes\n\nExclusion Criteria:\n\n* Currently pregnant\n* Use medications known to affect glucose metabolism (immunosuppressive medications, cancer medications, or high dose steroids), unless prescribed for Type 2 Diabetes management\n* Prior diagnosis of autoimmune disease, cancer, or a cognitive or perceptual disability that would inhibit following directions of study staff\n* Allergies or intolerance to milk, soy, or palm oil",true,"ALL","14 Years","18 Years",{"count":22,"type":23},175,"ESTIMATED","OBSERVATIONAL","This research study collects health-related information and blood samples to better understand how body composition, lifestyle habits, and diet influence meta-inflammatory monocytes (MiMos) in adolescents. The hypothesis of this study is that adolescents at risk for metabolic disease have enhanced MiMo related activities leading to insulin resistance.",[27,28,29,30,31],"Type 2 Diabetes","Insulin Resistance","Obesity","Metabolic Disease","PreDiabetes","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2023-09-06",{"date":40,"type":23},"2027-09",{"name":42,"class":43},"University of Michigan","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":44},"100053983","risk-informed-shared-decision-making-engagement-strategy-for-patients-with-prediabetes-100053983","NCT07553325","Risk-informed Shared-decision Making Engagement Strategy for Patients With Prediabetes","Pilot Trial of a Risk-informed Shared-decision Engagement Strategy","RISE","Inclusion Criteria:\n\n* prediabetes based on most recent HbA1c (5.7-6.4%) or fasting plasma glucose (100-125 mg\u002FdL) in prior 12 months\n* active patient portal account (MyChart)\n* patient receiving primary care at Johns Hopkins Community Physicians in Frederick\n* have overweight or obesity (BMI ≥ 25 kg\u002Fm2)\n\nExclusion Criteria:\n\n* have diabetes (HbA1c \\> 6.4% in prior 6 months or on diabetes registry)\n* have dementia\n* previously participated in the Diabetes Prevention Program (DPP)","75 Years",{"count":55,"type":23},120,"INTERVENTIONAL",[58],"NA","The goal of this clinical trial is to learn if knowing risk for diabetes can help adult patients with prediabetes take steps to get care and prevent diabetes. The main questions it aims to answer are:\n\n* Does a shared-decision making visit with a health care team member to talk about the participant's diabetes risk increase participants' taking steps to prevent diabetes?\n* Does a simple message in the patient portal about the participant's diabetes risk increase participants' taking steps to prevent diabetes?\n\nResearchers will compare the visit with usual care at the clinic to see if the visit increases participants' taking steps to prevent diabetes. Separately, the researchers will compare the patient message with usual care at the clinic to see if the message increases participants' taking steps to prevent diabetes.\n\nParticipants will:\n\n* Complete surveys at the beginning of the study and up to 2 additional surveys\n* If the participant falls into the shared decision-making group, the participant will have one 30-minute visit with a healthcare team member to talk about risk of diabetes and how to lower it.",[61,62],"Prediabetes","Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)",[64,65,66],"shared decision-making","diabetes risk","diabetes prevention","NOT_YET_RECRUITING",{"date":35,"type":36},{"date":70,"type":23},"2026-08-01",{"date":72,"type":23},"2028-04-01",{"name":74,"class":43},"Johns Hopkins University",{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":17,"sex":18,"minAge":82,"maxAge":53,"enrollmentInfo":83,"targetDuration":4,"studyType":56,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100634955","effects-of-exogenous-ketones-on-cognitive-function-in-older-adults-with-prediabetes-100634955","NCT07546409","Effects of Exogenous Ketones on Cognitive Function in Older Adults With Prediabetes?","Can Exogenous Ketone Supplementation Compensate for Glucose Hypometabolism and Improve Cognitive Processing Speed in Veterans With Prediabetes?","Inclusion Criteria:\n\n* Age 60 to 75 years\n* Able to provide written informed consent\n* Fluent in English\n* No diagnosed cognitive impairment or dementia\n\nClassified as either:\n\n* Prediabetes (based on American Diabetes Association criteria), or Normal glucose regulation (control group)\n* Medically stable and cleared to undergo positron emission tomography and magnetic resonance imaging\n* Willing to comply with study procedures, including metabolic testing, supplement ingestion, and neuroimaging\n\nExclusion Criteria:\n\n* Diagnosis of mild cognitive impairment, dementia, or other neurodegenerative disorder\n* Diagnosis of type 1 diabetes or type 2 diabetes\n* Use of glucose-lowering medications (e.g., insulin, metformin, glucagon-like peptide-1 receptor agonists)\n* History of major neurological disorder (e.g., stroke, traumatic brain injury with loss of consciousness \\>30 minutes, epilepsy, multiple sclerosis)\n* Major psychiatric disorder not stable on treatment\n* Uncontrolled hypertension or significant cardiovascular disease\n* Severe renal, hepatic, or gastrointestinal disease that may affect supplement metabolism\n* Contraindications to magnetic resonance imaging (e.g., non-compatible implanted devices, severe claustrophobia)","60 Years",{"count":84,"type":23},20,[58],"Brief Summary\n\nThe goal of this clinical trial is to learn whether older adults with prediabetes, but no diagnosed cognitive impairment, show early changes in brain energy use and thinking speed compared to older adults with normal blood sugar levels. The study will also test whether a single dose of an exogenous ketone supplement can improve brain energy use and cognitive processing speed.\n\nThe main questions it aims to answer are:\n\nDo older adults with prediabetes have lower brain glucose uptake and slower cognitive processing speed compared to those with normal glucose levels?\n\nDoes a single dose of an exogenous ketone monoester supplement improve cognitive processing speed and brain glucose uptake?\n\nResearchers will compare older adults with prediabetes to older adults with normal glucose levels to determine whether differences exist in brain glucose metabolism and cognitive performance. In a subset of participants, researchers will also compare brain and cognitive outcomes before and after consuming a ketone monoester supplement (DeltaG, Oxford, England).\n\nParticipants will:\n\nComplete metabolic testing to determine glucose status\n\nUndergo brain imaging using fluorodeoxyglucose positron emission tomography combined with magnetic resonance imaging (18FDG-PET\u002FMRI) while performing a cognitive processing speed task\n\nConsume a single dose of a commercially available ketone monoester supplement during one study visit\n\nComplete cognitive testing during imaging to measure processing speed and brain activity\n\nThe results of this study will help determine whether early metabolic dysfunction is linked to reduced brain energy use and whether ketones can temporarily support brain function in individuals at risk for dementia.",[61,88],"Healthy (Controls)",[90,28,91,92,93,94,95,96,97,98,99,100,101,102,103,104],"Prediabetic State","Brain Glucose Metabolism","Cerebral Glucose Uptake","Fluorodeoxyglucose F18","Positron-Emission Tomography","Magnetic Resonance Imaging","Functional Magnetic Resonance Imaging","Cognitive Dysfunction","Dementia","Aging","Processing Speed","Ketone Bodies","beta-Hydroxybutyrate","Neuroimaging","Brain Energy Metabolism","2026-06-30",{"date":107,"type":36},"2026-07-02",{"date":109,"type":36},"2025-05-20",{"date":111,"type":23},"2027-05-31",{"name":113,"class":43},"University of Alabama at Birmingham",2,{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":17,"sex":18,"minAge":123,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":56,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":44},"100642973","food-and-metabolism-study-100642973","NCT07624500","Food and Metabolism Study","Effects of Avocado on Triglyceride Metabolism in Individuals With Insulin Resistance","FAM","Inclusion Criteria:\n\n* Men or women, 40-70 years of age.\n* Fasting triglycerides (TG) \\>115 mg\u002FdL.\n* Insulin resistance as measured by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) \\>2.5.\n* Able to provide informed consent.\n* Able to comply with and perform the procedures requested by the protocol, specifically eat all the meals and snacks provided by the study which will be almost all your food (\\~ 80% of calories per day).\n* Able to come to the clinic up to 6 times during the study.\n* Able to maintain usual physical activity pattern.\n* Able to avoid\u002Fabstain from alcohol and vigorous physical activity for 24 hours prior to and during study visit.\n\nExclusion Criteria:\n\n* Men and women with known or suspected intolerance, allergies or hypersensitivity to study foods or interventions.\n* Fasting blood sugar ≥125 mg\u002FdL. Men and women with blood pressure \\>160 mmHg (systolic) \u002F 100 mmHg (diastolic) at the screening visit.\n* Men and women with history of diabetes cardiovascular events, respiratory, renal, gastrointestinal, hepatic or eye disease or surgery- within a year.\n* Men and women who have or had cancer other than non-melanoma skin cancer in the past 5 years.\n* Men and women taking over the counter or prescription medications or dietary supplements that may interfere with study procedures or endpoints.\n* Men and women who are on a specialized diet (vegan, vegetarian, keto, etc.). - - Men and women who consume nuts or peanuts daily or most days of the week.\n* Men and women who are not weight stable (+\u002F-10lbs in previous 2 months). Men and women who have excessive use of drugs or alcohol (ie., addictions) within the past 2 years.\n* Men and women with documented physical or mental disease\u002Fcondition, which might limit participation in or completion of the study or, that, in the opinion of the investigator, could interfere with the interpretation of the study results.\n* Women who are known to be pregnant or who are intending to become pregnant over the course of the study.\n* Women who are lactating.\n* Major trauma or a surgical event within 2 months (or longer depending on trauma or event) and after consultation with PI. Has used antibiotics within the previous 2 months.\n* History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating) diagnosed by a health professional.\n* Excessive coffee and tea consumers (\\> 4 cups\u002Fd).\n* Donated blood within the last 3 months.\n* Women who are taking an unstable dose and brand of hormonal contraceptives and\u002For a stable dose and brand for less than 6 months.\n* Unusual working hours (working overnight).","40 Years","70 Years",{"count":126,"type":23},82,[58],"In this study, Investigators are interested in looking at the influence of eating avocados regularly, which are rich in healthy fats, fibers, and unique carbohydrates, on triglyceride and glucose metabolism in people with prediabetes and insulin resistance.",[61,28,130,131],"Triglycerides","Lipids Metabolism",[130,133,134,135],"Insulin resistance","Glucose metabolism","Lipids metabolism","2026-06-29",{"date":138,"type":36},"2026-07-01",{"date":140,"type":36},"2026-06-03",{"date":142,"type":23},"2027-12-31",{"name":144,"class":145},"Clinical Nutrition Research Center, Illinois Institute of Technology","INDUSTRY",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":17,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":56,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":44},"100524940","ketogenic-diet-and-diabetes-demonstration-project-100524940","NCT06115265","Ketogenic Diet and Diabetes Demonstration Project","KDDP","Inclusion Criteria:\n\n* Men and women ≥ 18 years old\n* BMI ≥27 kg\u002Fm2\n* Hemoglobin A1c ≥ 5.7% and\u002For fasting plasma glucose of 100-125 mg\u002FdL\n\nExclusion Criteria:\n\n* Known clinical cardiovascular disease (i.e. prior stroke, myocardial infarction, peripheral artery disease)\n* LDL cholesterol ≥ 190 mg\u002FdL\n* Triglycerides ≥ 500 mg\u002FdL\n* History of type 1 diabetes\n* History of diabetic ketoacidosis\n* Individuals requiring insulin\n* Advanced renal disease\n* Advanced liver disease\n* Terminal cancer\n* Pregnancy",{"count":154,"type":23},40,[58],"KDDP is a prospective, 12-month pilot study comparing the effects of a novel lifestyle program, the Ketogenic Diet and Diabetes Demonstration Project (KDDP) to those of the National Diabetes Prevention Program (NDDP). KDDP is modeled to mimic the delivery platform of NDPP with the exception that participants in KDDP will be placed on a medically-supervised ketogenic diet, and participants in NDPP will be placed on a low fat diet.\n\nThe purpose of this study is to compare the metabolic effects of the KDDP and the NDPP on glycemic control, lipid parameters, blood pressure, heart rate, weight, and coronary artery calcium scores in individuals with either type 2 diabetes or prediabetes.",[27,31,29,158],"Ketogenic Dieting","2026-06-26",{"date":105,"type":36},{"date":162,"type":36},"2023-09-05",{"date":164,"type":23},"2026-10-01",{"name":166,"class":43},"University of New Mexico",{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":56,"phases":177,"briefSummary":178,"conditions":179,"keywords":180,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":44},"100643089","trial-of-cgm-technology-in-persons-living-with-prediabetes-100643089","NCT07639593","Trial of CGM Technology in Persons Living With Prediabetes","Trial of Continuous Glucose Monitoring (CGM) Technology in Persons Living With Prediabetes","CGM","Inclusion Criteria:\n\n* Subjects affiliated with one of the two institutional ambulatory clinics participating in this study who are meeting criteria for prediabetes listed on American Diabetes Association website, which includes A1c = or \\> than 5.7% and \\\u003C or = 6.4%, who also have reliable access to a smartphone device compatible with the CGM application\n* Greater than or equal to 18 years old\n\nExclusion Criteria:\n\n* Subjects who have been diagnosed with type 1 or type 2 diabetes mellitus, as defined as A1c \\> or = 6.5%\n* Subjects who do not have reliable access to a smartphone device compatible with the CGM application\n* Pregnant patients",{"count":176,"type":23},100,[58],"Continuous glucose monitor (CGM) technology has become increasingly prevalent in the population and has the ability to transform care of patients living with prediabetes. While the technology was initially utilized primarily by patients living with type 1 diabetes using insulin pump therapy, it has become more widely used as part of care in patients living with type 1 or 2 diabetes on any kind of insulin therapy.",[61],[181,182,183],"Continuous Glucose Monitoring","A1C (or HbA1c)","diabetes","2026-06-23",{"date":186,"type":36},"2026-06-24",{"date":188,"type":23},"2026-08",{"date":190,"type":23},"2027-03",{"name":192,"class":43},"Wake Forest University Health Sciences",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":18,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":204,"conditions":205,"keywords":209,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":4},"100644615","exocrine-endocrine-pancreatic-crosstalk-precision-pathways-to-reframe-diabetes-pathophysiology-100644615","NCT07670871","Exocrine-Endocrine Pancreatic Crosstalk: Precision Pathways to Reframe Diabetes Pathophysiology","EXPAND","Inclusion Criteria:\n\n* Adults aged 20 to 78 years.\n* Ability and willingness to provide written informed consent.\n* Eligibility for one of the study cohorts:\n* Individuals undergoing pancreatectomy for non-endocrine pancreatic disease.\n* Individuals with pancreatic ductal adenocarcinoma undergoing pancreatectomy.\n* Individuals with chronic pancreatitis or a previous episode of acute pancreatitis.\n* Individuals at increased risk of type 2 diabetes mellitus, including impaired fasting glucose and\u002For impaired glucose tolerance.\n* Individuals with newly diagnosed type 2 diabetes mellitus.\n* Ability to undergo study-related metabolic assessments and sample collection procedures.\n\nExclusion Criteria:\n\n* Age \\\u003C20 years or \\>78 years.\n* Inability or unwillingness to provide informed consent.\n* Pregnancy or breastfeeding.\n* Diagnosis of type 1 diabetes mellitus.\n* Participation in another interventional clinical trial involving an investigational medicinal product within 30 days before enrollment.\n* Clinical conditions that preclude completion of the planned metabolic assessments.\n* Inability to comply with study procedures.","20 Years","78 Years",{"count":203,"type":23},440,"The EXPAND study is a prospective observational study designed to investigate the biological mechanisms underlying the heterogeneity of type 2 diabetes and related metabolic disorders.\n\nThe study will enroll adults with and without pancreatic disease, including patients undergoing pancreatic surgery, individuals with chronic pancreatitis, subjects at high risk of type 2 diabetes, and patients with newly diagnosed type 2 diabetes. Clinical, metabolic, imaging, genetic, microbiome, and molecular data will be integrated to identify distinct metabolic endotypes and to investigate the interactions between the exocrine pancreas, endocrine pancreas, and adipose tissue. The ultimate goal is to improve the understanding of diabetes pathophysiology and support the development of precision medicine approaches.",[206,207,61,208],"Type 2 Diabetes Mellitus (T2DM)","Chronic Pancreatitis","Pancreatic Neoplasms",[210,211,212,213,214,215,216,217,218,219,220,221,222,223],"Metabolic Endotypes","Beta Cell Function","Insulin Secretion","Insulin Sensitivity","Exocrine Pancreas","Endocrine Pancreas","Pancreatic Crosstalk","Precision Medicine","Glucose Metabolism","Oral Glucose Tolerance Test","Genetic Risk Score","Fat Adipose Tissue","Hyperglycemic Clamp","Microbiome","2026-06-22",{"date":159,"type":36},{"date":227,"type":23},"2026-09",{"date":229,"type":23},"2031-09",{"name":231,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":17,"sex":18,"minAge":20,"maxAge":239,"enrollmentInfo":240,"targetDuration":4,"studyType":56,"phases":242,"briefSummary":243,"conditions":244,"keywords":245,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":4},"100643858","time-to-healthy-lifestyle-habit-using-digital-health-tools-in-adults-at-risk-of-diabetes-100643858","NCT07667361","Time to Healthy Lifestyle Habit Using Digital Health Tools in Adults at Risk of Diabetes","Time to Healthy Lifestyle Habit Using Digital Health Tools in Adults at Risk of Diabetes: A Randomized Clinical Trial With Time-to-Habit Analysis","Inclusion Criteria:\n\n* Adults(18-65 years) Risk of Diabetis\n\nExclusion Criteria:\n\n* Dignosed diabetis Pregnancy Any other contraindication to exericse praticipation","65 Years",{"count":241,"type":23},222,[58],"1. Background \\& Context\n\n   The Challenge: Type 2 Diabetes (T2D) is a major public health burden. Lifestyle changes are effective, but little is known about how long it actually takes to make these changes stick.\n\n   The Gap: Traditional trials look at outcomes at fixed time points (e.g., 12 weeks). We lack data on the specific timeline of habit formation, which is critical for designing scalable interventions.\n\n   The Setting: This study aligns with Saudi Vision 2030 by leveraging digital health to improve population wellness.\n2. Study Objectives\n\n   Primary Aim: To determine if a structured digital intervention accelerates the time to habit adoption compared to standard education.\n\n   Secondary Aims: To measure improvements in glucose control (HbA1c), overall physical activity levels, and quality of life.\n3. Study Design \\& Methods\n\n   Design: Randomized Controlled Trial (RCT).\n\n   Population: 222 adults at risk for diabetes.\n\n   Intervention (12 Weeks):\n\n   Group A (Experimental): Hybrid digital intervention with personalized support.\n\n   Group B (Control): Standard lifestyle education.\n\n   Follow-up: Total study duration of 24 weeks.\n\n   Primary Endpoint: \"Time to Habit.\" Defined as achieving ≥150 min\u002Fweek of moderate-to-vigorous physical activity (MVPA) for four consecutive weeks (verified by wearables).\n4. Statistical Analysis\n\nPrimary Analysis: We will use Kaplan-Meier curves to visualize the probability of achieving the habit over time, and Cox Proportional Hazards models to calculate the \"Hazard Ratio\" (the speed of adoption between the two groups).\n\nSecondary Analysis: General linear models for continuous outcomes (HbA1c, IPAQ, SF-12",[61],[246,247,248],"life style habits","prediabetis","time to habit formation","2026-06-18",{"date":251,"type":36},"2026-06-25",{"date":253,"type":23},"2027-01-01",{"date":255,"type":23},"2028-06-30",{"name":257,"class":43},"Imam Abdulrahman Bin Faisal University",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":18,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":56,"phases":268,"briefSummary":269,"conditions":270,"keywords":274,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":289},"100544195","effects-of-walking-in-greenspace-and-the-built-environment-in-adults-with-prediabetes-a-randomized-crossover-trial-100544195","NCT06365723","Effects of Walking in Greenspace and the Built Environment in Adults With Prediabetes: A Randomized Crossover Trial","Inclusion Criteria:\n\n* 25-64 years old.\n* Classified as overweight or obese with BMI 20.0-39.9 kg\u002Fm2 per self-report and a BMI of 20.0- 41.9 kg\u002Fm2 upon actual measure.\n* Documentation\\* of a PreD diagnosis within one year of enrollment by physician or primary care provider based on lab tests showing a fasted blood glucose of 100-125 mg\u002FdL, a 2-hour oral glucose tolerance test of 140-199 mg\u002FdL, or an HbA1c level of 5.7%-6.49%271; OR a study screening lab value of HbA1C within the aforementioned range.\n* Currently engaged in ≤100 min\u002Fweek of moderate to vigorous exercise -confirmed via a 7-day activity recall.\n* No exercise contraindications as assessed by the Physical Activity Readiness Questionnaire (PAR-Q) -this Questionnaire involves seven \"yes\" or \"no\" questions regarding an individual's health status. Answering \"yes\" to any one of these questions may require a prospective participant to acquire a written doctor's note stating they can safely participate in the trial's exercise intervention. The participant would not be enrolled until this doctor's note is received.\n* Stable weight over the last 3 months (less than 10% change).\n* Not currently pregnant, planning to become pregnant, or currently breastfeeding.\n* Willing to maintain current dietary and exercise habits, aside from any changes to be made per the study exercise protocol.\n* Must own a smartphone and be willing and able to download the Garmin Connect app\n* Ability to speak and understand English.\n* Any level of income\n* Any race\u002Fethnicity\n\nExclusion Criteria:\n\n* Individuals \\\u003C25 or \\>64: younger individuals may have not yet reached physiological maturity and in whom PreD prevalence is low; older individuals are more likely to have contraindications to PA and other comorbidities.\n* BMI \\\u003C20 or ≥42.\n* Individuals with an HbA1c level \\\u003C5.7% or \\>6.4%.\n* Currently engaged in \\>100 min\u002Fwk of PA.\n* Individuals with contraindications to exercise participation as indicated by the PAR-Q.\n* A self-reported physical\u002Fmental disability that would prevent them from being able to adhere to the intervention.\n* Past or current diagnosis of Diabetes (Type 1, 1.5 or 2) or use of diabetic medications (e.g. medications to control blood sugar)\n* Any history of a cardiovascular disease event (e.g. heart attack, ablation, pacemaker, stroke)\n* Current treatment for cancer or heart disease (lipid and hypertensive medications acceptable but will be tracked closely).\n* Any change within the last 3 months, or anticipated changes, of any medications that would affect study outcomes (e.g. medications for lipids, blood pressure, anxiety, depression)\n* The use of any medication that significantly interferes with the autonomic nervous system\n* Current tobacco or nicotine users, or those who have quit within the last six months\n* Excessive alcohol (on average\\>1 drinks\u002Fday for women and \\>2 drinks\u002Fday for men) or excessive recreational drug use (reported usage of once a week or more).\n* Unstable weight over the last three months (\\>10% change).\n* Those with major surgery planned or recent history of bariatric surgery (within last 2 years) or a history of other medical interventions that would interfere with study outcomes\n* Currently within one-year postpartum, currently pregnant, or planning to become pregnant during the study period.\n* Currently breastfeeding.\n* Unwilling to comply with study randomization procedures.\n* Unwilling to maintain current dietary and exercise habits, aside from any changes to be made per the study exercise protocol.\n* Current participation in another interventional clinical trial.\n* Previous randomization in this study.","25 Years","64 Years",{"count":267,"type":23},216,[58],"The goal of this randomized crossover trial is to compare the differences in psychological and physiological effects of walking in two different outdoor environments (urban\u002Fsuburban commercial environments vs. urban\u002Fsuburban nature areas\u002Fpreserves) in adults with prediabetes. The main questions it aims to answer are:\n\n* Do psychological measures of stress, anxiety, and affect improve more in one type of outdoor environment over the other?\n* Do physiological measures of stress improve more in one type of outdoor environment over the other?\n\nAs this is a crossover trial, participants will serve as their own controls. Researchers will compare both the psychological and physiological effects walking in the two types of outdoor environments.\n\nParticipants will:\n\n* Walk 150-minutes per week for six weeks in each of the two outdoor conditions.\n* Visit the clinic four times, including before and after each six-week walking period.\n* Collect saliva samples immediately proceeding or following the four clinic visits.\n* Return to their pre-study level of physical activity for a 5-week washout period between each of the two walking interventions.",[31,271,272,273],"Heart Rate Variability (HRV)","Stress and Anxiety","Stress Biomarkers",[275,276,277,278,279,280],"walking intervention","built environment","outdoor environment","prediabetes","stress","urban","2026-06-16",{"date":249,"type":36},{"date":284,"type":36},"2024-06-06",{"date":286,"type":23},"2028-11-30",{"name":288,"class":43},"University of Minnesota",3,{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":17,"sex":18,"minAge":298,"maxAge":299,"enrollmentInfo":300,"targetDuration":4,"studyType":56,"phases":302,"briefSummary":303,"conditions":304,"keywords":308,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":325,"leadSponsor":327,"locationsCount":44},"100641855","human-pilot-study-for-the-investigation-of-the-role-of-bilberry-and-olive-bioactives-on-oxidative-stress-parameters-and-inflammatory-markers-100641855","NCT07659028","Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers.","A Blinded Placebo-controlled Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers. Relevance in European Population","BIOTRANSFORM","Inclusion Criteria:\n\n* 30-50 years old,\n* BMI\\> 25 kg\u002Fm2\n* prediabetic stage\n* hsCRP\\> 2mg\u002F L\n* HbA1c 5,7-6,4%\n* Impaired fasting glucose (IFG)\n* Caucasian\n\nExclusion Criteria:\n\n* No signed informed consent\n* Supplementation or probiotic usage in the past 8 weeks\n* Chronic gastrointestinal, inflammatory or metabolic diseases\n* Alcohol misuse\n* Pregnancy or breastfeeding\n* Acute infection during the past month","30 Years","50 Years",{"count":301,"type":23},60,[58],"Numerous plant-based foods contain bioactive compounds, in particular polyphenols, which have antioxidant, anti-inflammatory, and metabolic regulatory effects. These so-called food bioactives (FB) are converted in the human organism, in particular by the gut microbiota and microsomal (liver\u002Fintestinal) metabolism, into numerous metabolites, which often represent the actual biologically active molecules. As part of the European HORIZON-MSCA Doctoral Network \"BioTransform,\" two such food models are being studied as examples: 1. Olive products (Olea europaea L.) - representative of the Mediterranean diet, rich in secoiridoids and phenylethanols (especially hydroxytyrosol and tyrosol). 2.\n\nBilberry \u002Fblueberry (Vaccinium myrtillus L.) - representative of the Central European diet, rich in anthocyanosides. Two parallel human intervention studies will be conducted, one in Graz (WP1, DC5) and one in Athens (WP1, DC3). These pilot studies will generate biological samples (blood, urine, stool) and investigate the extent to which taking these standardized dietary supplements influences glucose metabolism and markers of oxidative stress and low-grade inflammation.",[61,305,306,307],"Obesity & Overweight","Inflamation","Oxidative Stress",[309,310,311,312,313,314,315,316,317,318,319,320,321],"FOOD BIOACTIVES","FOOD BIOACTIVE COMPOUNDS","OLIVE PRODUCTS","BILBERRY PRODUCTS","OLEA EUROPEA L.","BILBERRY","VACCINUM MYRTILLOUS L.","GUT MICROBIOME","MICROBIOME MAPPING","IN VITRO","IN SILICO","BIOACTIVE COMPOUNDS","METABOLISM","2026-06-15",{"date":224,"type":36},{"date":138,"type":23},{"date":326,"type":23},"2029-10-31",{"name":328,"class":43},"National and Kapodistrian University of Athens",{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":335,"eligibilityCriteria":336,"healthyVolunteers":17,"sex":18,"minAge":337,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":56,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":345,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":352},"100524721","a-randomized-comparison-of-stage-based-care-versus-risk-factor-based-care-for-prevention-of-cardiovascular-events-100524721","NCT06112418","A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events","A Randomized Comparison of Cleerly Coronary Artery Disease Stage-Based Care Versus Risk Factor-Based Care for Primary Prevention of Cardiovascular Events","TRANSFORM","Inclusion Criteria:\n\n1. Provided electronic or written informed consent\n2. Men \\> 55, women \\> 65 years of age\n3. Type 2 diabetes mellitus requiring pharmacologic therapy, prediabetes (most recent HbA1c 5.7 to 6.4% and\u002For fasting glucose 100-125 mg\u002FdL \\[5.6-6.9 mmol\u002FL\\]) and\u002For metabolic syndrome. Metabolic syndrome is defined as \\> 3 of the following criteria (International Diabetes Federation 2006):\n\n   * Body mass index ≥ 27 kg\u002Fm2 or abnormal waist circumference defined as ≥ 80 cm (31.5 inches) for women, ≥ 94 cm (37 inches) for men; for South and East Asian men (e.g., Asian Indian, Chinese, Japanese) ≥ 90 cm (35.4 inches)\n   * Fasting triglycerides ≥ 150 mg\u002FdL (1.7 mmol\u002FL) or treated hypertriglyceridemia\n   * HDL-cholesterol (HDL-C) \\\u003C 40 mg\u002FdL (1.03 mmol\u002FL) in men, \\\u003C50 mg\u002FdL (1.29 mmol\u002FL) in women or treatment for this lipid abnormality\n   * Systolic blood pressure (BP) ≥ 130 and\u002For diastolic BP≥ 85 mm Hg and\u002For treated hypertension\n   * Fasting blood glucose ≥ 100 mg\u002FdL (5.6 mmol\u002FL) or HbA1c ≥ 5.7%\n4. Have a device (e.g., smartphone, tablet, computer) for communication with the central cardiologist-led team managing drug treatment for the personalized care group\n\nExclusion Criteria:\n\n1. History of symptomatic CVD defined as prior MI, exertional or unstable angina, ischemic stroke, claudication, arterial revascularization for atherosclerosis or other CVD being actively managed by a cardiologist, e.g. atrial fibrillation, heart failure\n2. Planned arterial revascularization\n3. Inability to complete screening CCTA or any condition that would increase the risk associated with CCTA or increase likelihood of uninterpretable scan including:\n\n   1. eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation (www.kidney.org\u002Fprofessionals\u002Fkdoqi\u002Fgfr\\_calculator)\n   2. Allergy to iodinated contrast or history of contrast-induced nephropathy (including adverse reaction to contrast at screening CCTA) or screening laboratory values consistent with untreated hyperthyroidism. Participants with elevated thyroid-stimulating hormone (TSH) may be enrolled but should be referred to their physician for evaluation for treatment.\n   3. Thyroid cancer in the previous five (5) years or planned radioactive iodine treatment\n   4. Weight \\> 300 lbs. (136 kg) or above manufacturer-recommended limit for scanner and table at the site\n   5. Inability to hold breath for \\> 10 seconds\n   6. Active arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., \\> 80 beats per minute at screening or prior to CCTA)\n   7. Contraindication to dosing with beta blocker or nitroglycerin on day of screening CCTA\n   8. Any other factor that, in the opinion of the investigator, would increase participant risk or increase the chance of an uninterpretable CCTA\n4. Unsuitable as a trial participant in the opinion of the investigator for reasons including significant left main stenosis (e.g. ≥ 70%; site will be notified by Cleerly), other health condition with life expectancy \\\u003C 3 years or being at risk of poor compliance with study procedures (e.g., active substance abuse or untreated mental illness that, in the opinion of the investigator, is likely to adversely affect adherence or retention)","55 Years",{"count":339,"type":23},7500,[58],"TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.",[343,31,344],"Diabetes Mellitus, Type 2","Metabolic Syndrome",{"date":281,"type":36},{"date":347,"type":36},"2024-03-06",{"date":349,"type":23},"2029-03-05",{"name":351,"class":145},"Cleerly, Inc.",124,{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":53,"enrollmentInfo":361,"targetDuration":4,"studyType":56,"phases":363,"briefSummary":365,"conditions":366,"keywords":369,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":44},"100641577","phase-4-mazdutide-for-adults-with-prediabetes-a-randomized-double-blind-placebo-controlled-trial-dream-pre-100641577","NCT07654062","Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)","Efficacy and Safety of Mazdutide in Adults With Prediabetes: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial (DREAM-PRE)","DREAM-PRE","Inclusion Criteria:\n\n1. Voluntarily signed written informed consent prior to any study procedures\n2. Age 18 to 75 years (inclusive) at the time of signing informed consent; male or female\n3. Prediabetes confirmed by central laboratory at screening, meeting at least one of the following criteria per Chinese Diabetes Society (CDS) standards, and not meeting diagnostic criteria for diabetes:\n\n   * Impaired Glucose Tolerance (IGT): 75g OGTT 2-hour plasma glucose\n\n     * 7.8 mmol\u002FL and \\\u003C11.1 mmol\u002FL\n   * Impaired Fasting Glucose (IFG): fasting plasma glucose ≥6.1 mmol\u002FL and \\\u003C7.0 mmol\u002FL\n   * Elevated HbA1c: 5.7% ≤ HbA1c \\\u003C 6.5% (39-48 mmol\u002Fmol)\n4. BMI ≥22.0 kg\u002Fm² at screening\n5. Self-reported body weight change \\\u003C10% within 3 months prior to screening; not currently participating in any organized weight-loss program\n6. Able to understand study requirements, complete all planned visits and examinations, self-administer once-weekly subcutaneous injections, and use the study app for daily monitoring\n\nExclusion Criteria:\n\n1. Confirmed diabetes at screening (FPG ≥7.0 mmol\u002FL, OGTT 2h-PG ≥11.1 mmol\u002FL, or HbA1c ≥6.5%); or prior confirmed diagnosis of type 1 diabetes, type 2 diabetes, or other specific types of diabetes. Prior gestational diabetes in whom blood glucose has returned to prediabetes levels after delivery is NOT grounds for exclusion.\n2. Continuous use of any antidiabetic medication for more than 7 days within 3 months prior to screening, including: biguanides (metformin), alpha-glucosidase inhibitors (acarbose, voglibose, miglitol), sulfonylureas (glimepiride, gliclazide, glipizide, glibenclamide), glinides (repaglinide, nateglinide), thiazolidinediones (pioglitazone, rosiglitazone), DPP-4 inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin), SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, ertugliflozin), insulin (any formulation), or traditional Chinese medicine with confirmed glucose-lowering indication.\n3. Use of any of the following within 6 months prior to screening (regardless of duration): GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, benaglutide, etc.), GIP\u002FGLP-1 dual agonists (tirzepatide, etc.), any dual or triple agonist containing GLP-1R and\u002For GCGR components (including mazdutide), or any GLP-1 class investigational drug in clinical development.\n4. Use of any prescription weight-loss medication within 3 months prior to screening (regardless of duration), including orlistat, naltrexone\u002Fbupropion combination, phentermine\u002Ftopiramate combination, or any weight-loss drug approved in China or in clinical development. Over-the-counter dietary supplements are not excluded but must be recorded.\n5. Spontaneous body weight change ≥10% within 3 months prior to screening (based on self-report and\u002For available medical records), or currently participating in any organized weight-loss program (including commercial weight-loss plans or weight-loss interventions in other clinical trials).\n6. Prior bariatric or metabolic surgery including Roux-en-Y gastric bypass, sleeve gastrectomy, adjustable gastric banding, biliopancreatic diversion, intragastric balloon placement, or other bariatric surgery.\n7. Prior history of acute pancreatitis (confirmed by imaging or surgery) or chronic pancreatitis; or serum amylase \\>3× ULN or serum lipase \\>3× ULN at screening.\n8. Personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2); first-degree family history of MTC or MEN2; or serum calcitonin ≥50 ng\u002FL at screening.\n9. Any of the following within 6 months prior to screening: acute myocardial infarction (STEMI or NSTEMI), ischemic or hemorrhagic stroke, transient ischemic attack (TIA), coronary revascularization (PCI or CABG), or hospitalization for unstable angina.\n10. NYHA Class III or IV heart failure. (NYHA Class I and II are not grounds for exclusion.)\n11. Clinically significant arrhythmia on 12-lead ECG at screening, including:\n\n    Mobitz Type II or third-degree atrioventricular block, sustained ventricular tachycardia (≥30 seconds or requiring cardioversion), QTcF \\>500 ms, or resting heart rate \\\u003C50 bpm (in subjects not using beta-blockers or calcium channel blockers).\n12. Uncontrolled hypertension: confirmed mean systolic blood pressure ≥180 mmHg and\u002For mean diastolic blood pressure ≥110 mmHg on repeated measurements at screening despite antihypertensive therapy. Subjects with controlled blood pressure on a stable antihypertensive regimen (stable for ≥4 weeks prior to screening) are allowed to enroll.\n13. ALT \\>3× ULN, AST \\>3× ULN, or total bilirubin \\>2× ULN at screening (except confirmed Gilbert's syndrome with normal direct bilirubin).\n14. eGFR (CKD-EPI) \\\u003C45 mL\u002Fmin\u002F1.73 m² at screening. Subjects with eGFR 45-60 mL\u002Fmin\u002F1.73 m² may enroll with enhanced renal function monitoring.\n15. Any of the following gastrointestinal conditions: known gastroparesis (confirmed by gastric emptying study or clinical diagnosis), inflammatory bowel disease (Crohn's disease or ulcerative colitis, active or remission), short bowel syndrome, prior gastrointestinal surgery likely to affect drug absorption (excluding simple appendectomy and laparoscopic cholecystectomy), or other serious gastrointestinal disease likely to significantly affect drug tolerability or absorption.\n16. Diagnosis or active treatment of any malignancy within 5 years prior to screening.\n17. Positive urine pregnancy test at screening, currently breastfeeding, or planning pregnancy during the 48-week study period.\n18. Known allergy to mazdutide or any excipient in its formulation; or prior serious allergic reaction to any GLP-1 class drug (defined as angioedema, anaphylactic shock, or allergic reaction requiring hospitalization).\n19. Participation in any other interventional clinical trial within 3 months prior to screening (excluding purely observational or epidemiological studies not involving investigational drugs or devices), or currently enrolled in any other clinical trial.\n20. Currently on long-term systemic corticosteroids (expected continuous use \\>14 days, oral or intravenous); or currently using drugs known to significantly affect body weight or glucose metabolism that cannot be discontinued or substituted, including antipsychotics (olanzapine, clozapine, quetiapine, etc.), valproate sodium, or lithium.\n21. History of alcohol abuse within 1 year prior to screening, defined as daily consumption \\>3 standard drink units (men) or \\>2 standard drink units (women) sustained for \\>3 months (1 standard drink unit ≈ 10g pure alcohol).",{"count":362,"type":23},150,[364],"PHASE4","Prediabetes affects millions of adults worldwide and carries a high risk of progression to type 2 diabetes. Mazdutide is a once-weekly injectable drug that activates both GLP-1 and glucagon receptors, lowering blood sugar and body weight simultaneously.\n\nThis study (DREAM-PRE) tests whether mazdutide can help adults with prediabetes return to normal blood sugar levels. Approximately 150 adults aged 18-75 years with prediabetes and BMI ≥22 kg\u002Fm² will be randomly assigned in equal numbers to one of three groups: mazdutide 4 mg once weekly, mazdutide 6 mg once weekly, or placebo once weekly. All participants also receive standardized diet and exercise guidance throughout the study.\n\nTreatment lasts 24 weeks, followed by 24 weeks of off-drug follow-up to see whether any benefits are maintained. The main question is: what proportion of participants achieve completely normal blood sugar (normal HbA1c, fasting glucose, AND glucose tolerance test) after 24 weeks of treatment? The study is conducted at approximately 10 hospitals across China.",[61,367,368],"Impaired Fasting Glucose","Impaired Glucose Tolerance (Prediabetes)",[370,371,372,61,373,374,375,133,376],"Mazdutide","IBI362","GLP-1R\u002FGCGR dual agonist","Diabetes prevention","Normal glucose regulation","Beta-cell function","Weight loss","2026-06-13",{"date":379,"type":36},"2026-06-17",{"date":381,"type":23},"2026-07",{"date":383,"type":23},"2029-07",{"name":385,"class":386},"Shandong Provincial Hospital","OTHER_GOV",{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":17,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":397,"conditions":398,"keywords":400,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":44},"100641794","personality-traits-and-biochemical-risk-phenotypes-100641794","NCT07653048","Personality Traits and Biochemical Risk Phenotypes","Personality Traits and Biochemical Risk Phenotypes in Adults Undergoing Routine Health Assessment","PHEBiP","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Undergoing routine health assessment\n* Completion of the Five-Factor Personality Inventory (FFPI)\n* Availability of routine laboratory test results\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Incomplete FFPI assessment\n* Missing or incomplete laboratory data\n* Refusal or inability to provide informed consent",{"count":396,"type":23},1000,"This prospective observational study investigates the association between personality traits and routine laboratory abnormalities in adults undergoing routine health assessment. Personality traits are assessed using the Five-Factor Personality Inventory (FFPI), while biochemical data are obtained from routine laboratory testing, including markers of glycemic status, liver function, lipid metabolism, renal function, and complete blood count parameters.\n\nThe primary objective of the study is to evaluate the association between FFPI personality trait scores and the total number of laboratory abnormalities identified during routine clinical evaluation. Secondary analyses will examine associations between personality traits and glycemic status, fasting plasma glucose concentration, liver function markers, lipid profile parameters, renal function indicators, complete blood count parameters, and the total number of laboratory abnormalities.\n\nThe findings may contribute to a better understanding of the relationship between psychological characteristics and biological health indicators and may support the development of more personalized approaches to health promotion, risk assessment, and disease prevention.",[61,399,344],"Hyperglycemia",[401,402,61,399,403,404,405,406],"Personality Traits","Biomarkers","Occupational Health","Five-Factor Personality Inventory","Laboratory Abnormalities","Routine Health Assessment","2026-06-11",{"date":379,"type":36},{"date":410,"type":36},"2024-10-01",{"date":412,"type":23},"2027-09-01",{"name":414,"class":43},"Medical Center TOPMED",{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":17,"sex":18,"minAge":298,"maxAge":337,"enrollmentInfo":423,"targetDuration":4,"studyType":56,"phases":424,"briefSummary":425,"conditions":426,"keywords":427,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":435,"leadSponsor":437,"locationsCount":44},"100601127","training-induced-muscle-adipose-ev-communication-100601127","NCT07106450","Training Induced Muscle-Adipose EV Communication","Muscle-derived Extracellular Vesicles and Their Interactions With Adipocytes in Human Metabolic Dysfunction","TIMER2","Inclusion Criteria:\n\n* Age 30-55 years\n* Sedentary lifestyle (exercise \\\u003C1 day\u002Fweek for at least 3 months prior to enrollment)\n* Able to provide informed consent\n* For Control Group: BMI \\\u003C 27 kg\u002Fm², normal glucose tolerance, no more than 1 feature of metabolic syndrome\n* For Prediabetic Group: BMI \\> 30 kg\u002Fm², at least 3 features of metabolic syndrome including prediabetes (defined as fasting plasma glucose 100-125 mg\u002FdL OR 2-hour post-load glucose on 75g OGTT 140-199 mg\u002FdL OR HbA1C 5.7-6.4%)\n\nExclusion Criteria:\n\n* Pregnancy (confirmed by pregnancy test in women of childbearing potential)\n* Type 2 diabetes mellitus\n* Cardiovascular contraindications to resistance exercise\n* Medical conditions that would interfere with muscle or adipose tissue biopsy procedures\n* Use of medications that significantly affect glucose metabolism or exercise response\n* Active participation in structured exercise programs (\\>1 day\u002Fweek) within 3 months of enrollment\n* Inability to safely participate in resistance exercise protocol",{"count":154,"type":23},[58],"This study examines how muscle cells communicate with fat cells through tiny packages called extracellular vesicles (EV) during exercise. These vesicles carry important molecules that may affect how the body processes sugar and fat. The research team observed significant variability in the adipose response to exercise, and used this variability to gain further insight into the mechanism through which mature microRNA-1 (miR-1) changes in adipose tissue. The investigators selected six subjects with the highest increase in miR-1 abundance in adipose tissue after exercise and compared them with the six subjects that had the most dramatic decrease in miR-1 abundance after exercise. The research team observed that participants intrinsically vary in their ability to endocytose EV into adipose tissue. It is unclear whether this variance in receptivity is a cause or consequence of the significant difference in EV-delivery of miR-1 to adipose tissue.",[61],[428,429,430],"muscle","extracellular vesicles","adipose","2026-06-08",{"date":433,"type":36},"2026-06-10",{"date":381,"type":23},{"date":436,"type":23},"2028-09-30",{"name":438,"class":43},"Yuan Wen",{"id":440,"slug":4,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":53,"enrollmentInfo":441,"targetDuration":4,"studyType":56,"phases":442,"briefSummary":59,"conditions":443,"keywords":444,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":448,"leadSponsor":449,"locationsCount":44},"100635487",{"count":55,"type":23},[58],[61,62],[64,65,66],"2026-06-04",{"date":431,"type":36},{"date":138,"type":23},{"date":72,"type":23},{"name":74,"class":43},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":18,"minAge":123,"maxAge":239,"enrollmentInfo":457,"targetDuration":4,"studyType":56,"phases":458,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":467,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":44},"100518034","effects-of-lean-pork-loin-intake-on-protein-homeostasis-and-glucose-regulation-in-prediabetic-adults-100518034","NCT06025292","Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults","PORK","Inclusion Criteria:\n\n* 1\\. Males and females ages 40-65 years.\n* 2\\. BMI 25 to ≤40 kg\u002Fm2 (or body fat % ≥25% in males or ≥36% in females)\n* 3\\. Capable of providing informed consent.\n* 4\\. COVID-19 negative and\u002For asymptomatic.\n* 5\\. Willing to abstain from drinking alcohol or consuming marijuana and CBD products during the 4-day study meal period\n* 6\\. HbA1c: 5.7-6.4% or fasting glucose 100-125 mg\u002FdL\n\nExclusion Criteria:\n\n* 1\\. Participant who does not\u002Fwill not eat animal protein sources.\n* 2\\. Allergy to wheat, soy, or common ingredients in plant-based protein products.\n* 3\\. Body mass index \\\u003C25 kg\u002Fm2 or \\>40 kg\u002Fm2.\n* 4\\. Hemoglobin \\\u003C10g\u002FdL at screening.\n* 5\\. Platelets \\\u003C150,000\u002FuL at screening.\n* 6\\. History of chemotherapy or radiation therapy for cancer in the 6 months prior to enrollment.\n* 7\\. History of gastrointestinal bypass\u002Freduction surgery.\n* 8\\. Pregnant or lactating individuals.\n* 9\\. History of a chronic inflammatory disease (e.g. Lupus, Crohn's disease)\n* 10\\. Currently receiving androgen (e.g., testosterone) or anabolic (e.g., GH, IGF-I) therapy.\n* 11\\. Currently using prescription blood thinning medications.\n* 12\\. Currently using corticosteroid medications (cortisone, hydrocortisone, prednisone, etc.).\n* 13\\. Unable or unwilling to suspend aspirin use for 7 days prior to Visit 3 and Visit 7.\n* 14\\. Unwilling to avoid using protein or amino-acid supplements during participation.\n* 15\\. Unwilling to fast overnight.\n* 16\\. Unwilling to avoid alcohol, marijuana and CBD products for the four study days.\n* 17\\. Participants on glucagon-like-peptide-1 receptor agonist (GLP-1-RA) medications for \\\u003C1 month or with less than one treatment dose (injection) every two weeks",{"count":84,"type":23},[58],"We will be directly comparing a high-quality protein diet composed primarily of lean pork loin (PORK) to a lower-quality plant-based protein diet (PLANT) in individuals with prediabetes on muscle and whole-body protein turnover and glucose regulation.",[461,61],"Hyperglycaemia (Non Diabetic)",[463,464,465,466],"Lean pork","Muscle Protein Synthesis","Protein","Plant-Based",{"date":431,"type":36},{"date":469,"type":36},"2024-09-11",{"date":471,"type":23},"2027-01-31",{"name":473,"class":43},"University of Arkansas",{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":82,"enrollmentInfo":482,"targetDuration":4,"studyType":56,"phases":484,"briefSummary":485,"conditions":486,"keywords":491,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":44},"100603043","interaction-between-inorganic-nitrate-supplementation-and-metformin-in-individuals-with-prediabetes-100603043","NCT07131384","Interaction Between Inorganic Nitrate Supplementation and Metformin in Individuals With Prediabetes","The Interaction Between Inorganic Nitrate Supplementation and Metformin on Exercise Capacity, Vascular Function, and Insulin Sensitivity in Individuals With Pre-Diabetes","NO3-PreDM","Inclusion Criteria:\n\n* Individuals who can communicate meaningfully with the investigator and can provide written consent.\n* Confirmed prediabetic individuals (ages 18-60 years old) (2-hour glucose of 140-199 mg\u002FdL following OGTT test or HbA1c between 5.7-6.4% tested on two occasions within 6 months).\n* Taking metformin (stable dose for at least a week) or naïve to metformin\n* Sedentary (\\\u003C1 day\u002Fweek of structured exercise)\n* Be able to perform exercise on a cycle ergometer without assistance\n* Stable medication regimen for the last 6 months\n* If female, have a normal menstrual cycle\n\nExclusion Criteria:\n\n* Estimated Glomerular filtration rate (GFR) ≤ 45\n* Body mass index ≥ 40 Kg\u002Fm2\n* HbA1c \\> 6.4%\n* Smokers within the last 5 years\n* Has experienced significant weight loss \\~3 kg in the last three months or is taking any weight loss drugs\n* Current medical condition that prohibits exercising at high intensities\n* Currently on hormone replacement of any kind\n* History of myocardial infarction, cerebrovascular event, acute or unstable disease other than pre-diabetes or obesity\n* Currently taking any of the following medications (calcium channel blockers, statins, ACE or renin inhibitors, angiotensin receptor blockers, organic nitrates (e.g., nitroglycerine) or recent regular use of inorganic nitrates, alpha- or beta-blockers, diuretics, proton pump inhibitors, PDE-5 inhibitors (e.g.,: Cialis, Viagra), or xanthine oxidase inhibitors (e.g.,: Allopurinol))\n* Oral antibiotic use within the previous four weeks, including over-the-counter antibacterial mouthwash or a mouthwash containing chlorhexidine and unwilling to discontinue use\n* Oral cancer\u002Fsevere oral disease\n* Uncontrolled hypertension (\\>140\u002F90)\n* Had hysterectomy or oophorectomy\n* Fetuses, neonates, children, prisoners, cognitively impaired, non-English speaking participants",{"count":483,"type":23},24,[58],"This study is examining whether short-term supplementation with inorganic nitrate, in the form of beetroot juice, can enhance blood vessel health, insulin sensitivity, and exercise capacity in individuals with prediabetes. We will be comparing the responses in individuals who are taking metformin to those who are naive to metformin. The results from this study may help identify non-pharmacological interventions in prediabetes.",[487,488,489,490,61],"Males","Females","Sedentary","Metformin",[492,493,494,495,213],"Prediabetic Individuals","Exercise Capacity","Vascular health","Inorganic nitrate","2026-06-02",{"date":140,"type":36},{"date":499,"type":36},"2026-01-01",{"date":501,"type":23},"2027-06-30",{"name":503,"class":43},"University of Virginia",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":18,"minAge":510,"maxAge":20,"enrollmentInfo":511,"targetDuration":4,"studyType":56,"phases":513,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":44},"100576254","effect-of-increased-physical-activity-and-stopping-evening-snacking-in-metabolic-health-in-youth-with-prediabetes-100576254","NCT06782906","Effect of Increased Physical Activity and Stopping Evening Snacking in Metabolic Health in Youth With Prediabetes","Inclusion Criteria:\n\n1. 12-18 years of age\n2. Having a diagnosis of prediabetes\n3. Engaging in frequent evening snacking\n4. Inadequate physical activity\n\nExclusion Criteria:\n\n1. Diagnosis of diabetes\n2. Significant history of chronic disease\n3. Evidence of significant liver or kidney disease;\n4. Any hormone replacement therapy; and\n5. Pregnancy.","12 Years",{"count":512,"type":23},80,[58],"Non-healthy eating habits and a lack of exercise contribute to prediabetes and type 2 diabetes (T2D). Evening snacking is linked to abnormal weight gain in adults and healthy adolescents. Most adolescents do not get enough exercise. This study aims to look at the benefits of more exercise and stopping evening snacking in youth with prediabetes. The study lasts 8 weeks, and participants will be randomly assigned to either an intervention group or a standard of care group.",[61],"2026-06-01",{"date":496,"type":36},{"date":519,"type":36},"2025-05-13",{"date":521,"type":23},"2029-09",{"name":523,"class":43},"Baylor College of Medicine",{"id":525,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":526,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":527,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":530,"leadSponsor":531,"locationsCount":44},"100516659",{"count":22,"type":23},[27,28,29,30,31],{"date":140,"type":36},{"date":38,"type":36},{"date":40,"type":23},{"name":42,"class":43},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":540,"enrollmentInfo":541,"targetDuration":4,"studyType":56,"phases":542,"briefSummary":543,"conditions":544,"keywords":545,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":553,"leadSponsor":555,"locationsCount":44},"100630744","fiber-mhealth-intervention-for-prediabetes-100630744","NCT07491653","Fiber mHealth Intervention for Prediabetes","Preliminary Examination of an Innovative mHealth-Based Dietary Fiber Intervention to Improve Outcomes in Young Adults With Prediabetes: A Feasibility Study","GO-FAR","Inclusion Criteria:\n\n* Pre-diabetes based on HbA1c\n* Young adult, aged 18-39 years\n* Reside near Tulsa metro area\n* Ability to access\u002Fuse a compatible smartphone\n* Proficient in English\n\nExclusion Criteria:\n\n* Suspected eating disorder\n* Current glucagon-like peptide-1 receptor agonist use\n* Food allergies or intolerances\n* Currently pregnant or breastfeeding","39 Years",{"count":512,"type":23},[58],"This is a single-arm feasibility trial to examine an mHealth intervention that combines high fiber education, home-delivered high fiber foods, and use of continuous glucose monitors.",[61],[546,547,548,549],"Diet","Young adults","Fiber","Diabetes","2026-05-28",{"date":516,"type":36},{"date":188,"type":23},{"date":554,"type":23},"2028-07-01",{"name":556,"class":43},"University of Oklahoma",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":563,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":18,"minAge":123,"maxAge":239,"enrollmentInfo":565,"targetDuration":4,"studyType":56,"phases":566,"briefSummary":567,"conditions":568,"keywords":569,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":578,"completionDateStruct":579,"leadSponsor":581,"locationsCount":4},"100640428","effects-of-postprandial-walking-and-resistance-snacking-on-glucose-responses-in-adults-with-metabolic-syndrome-100640428","NCT07620886","Effects of Postprandial Walking and Resistance Snacking on Glucose Responses in Adults With Metabolic Syndrome","Effects of Postprandial Walking and Brief Resistance Exercise Snacks on Continuous Glucose and Heart Rate Variability Responses in Adults With Metabolic Syndrome and Prediabetes: A Randomized Crossover Trial","BITE","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Adults aged 40 to 65 years\n* Presence of metabolic syndrome\n* Fasting glucose of 100 mg\u002FdL or higher or HbA1c of 5.7% or higher\n* Not regularly engaged in structured exercise training, defined as less than 150 minutes per week during the past year\n* Able to consume the standardized study meals\n* Able to wear a continuous glucose monitor and a chest strap heart rate monitor\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* History of major cardiovascular, cerebrovascular, respiratory, renal, hepatic, neurological, or other severe medical conditions that may affect study participation.\n* Uncontrolled hypertension, defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg.\n* Current use of medications associated with a high risk of hypoglycemia, such as insulin or sulfonylureas.\n* Initiation or dose change of insulin or oral glucose-lowering medications within the past 3 months.\n* Initiation or dose change of medications for hypertension, dyslipidemia, or diabetes within the past 3 months.\n* Musculoskeletal, neurological, or orthopedic conditions that limit safe participation in walking or body-weight resistance exercise, including severe knee, hip, back, or ankle pain.\n* Regular participation in moderate-to-vigorous exercise of 150 minutes or more per week during the past year.\n* Difficulty consuming the standardized study meals, including food allergy, dietary restrictions, or severe gastrointestinal symptoms.\n* Difficulty wearing a continuous glucose monitor or history of severe skin irritation or allergy to adhesive sensors.\n* Difficulty wearing a chest strap heart rate monitor or skin problems at the chest strap site.\n* Pregnancy or planned pregnancy.\n* Acute illness, infection, surgery, or hospitalization within the past month.\n* Current participation in another interventional study.\n* Any condition judged by the investigator to make participation unsafe or inappropriate.\n\nExclusion Criteria:\n\n\\-",{"count":7,"type":23},[58],"This study will examine whether light physical activity after meals can improve 24-hour glucose responses in adults with metabolic syndrome and prediabetes.\n\nParticipants will complete three experimental conditions in a randomized crossover order: prolonged sitting, 15 minutes of postprandial walking, and brief resistance exercise snacks consisting of squats and calf raises performed every 20 minutes during the postprandial period. Continuous glucose monitoring will be used to assess 24-hour glucose responses, and heart rate variability will be measured during the 2-hour postprandial period to evaluate acute autonomic responses.\n\nThe main outcome is 24-hour mean glucose derived from continuous glucose monitoring.",[344,61],[570,571,572,573,574,61,575],"Continuous glucose monitoring","Postprandial glucose","Exercise snack","Resistance exercise","Heart rate variability","Metabolic syndrome","2026-05-27",{"date":496,"type":36},{"date":322,"type":23},{"date":580,"type":23},"2026-10",{"name":582,"class":43},"Seoul National University",{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":17,"sex":18,"minAge":264,"maxAge":53,"enrollmentInfo":590,"targetDuration":4,"studyType":56,"phases":591,"briefSummary":592,"conditions":593,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":44},"100505824","the-effect-of-time-restricted-eating-in-cardiometabolic-health-100505824","NCT05866406","The Effect of Time-Restricted Eating in Cardiometabolic Health","TRE","Inclusion Criteria:\n\n* must be able to grant voluntary informed consent and comply with the study instructions\n* aged 25-75 years\n* men and women\n* body mass index 27-45 kg\u002Fm2\n* fasting plasma glucose 5.6-6.9 mmol\u002FL, or 2h oral glucose tolerance test plasma glucose 7.8-11.1 mmol\u002FL or haemoglobin A1C 39-46 mmol\u002Fmol or homeostasis model assessment-insulin resistance (HOMA-IR) score ≥2.73\n* self-reported habitual eating period ≥ 13 h per day\n\nExclusion Criteria:\n\n* shift worker\n* fasting \\>12 h\u002Fday more than once a week\n* vegan\n* \\> once a week no food intake after \\~1800 h\n* habitually waking up before \\~0400 h and sleeping before \\~2100 h\n* unstable weight (\\>5% change the last 2 months)\n* Clinical diagnosis of type 1 or 2 diabetes\n* Clinical diagnosis of sleep disorder\n* Clinical diagnosis of eating disorder\n* Clinical diagnosis of cancer in last 5 years\n* conditions that render subject unable to complete all testing procedures (including individuals with known allergies or contraindications to the medications used in this study)\n* use of medications that affect the study outcome measures or increase the risk of study procedures and that cannot be temporarily discontinued (e.g., steroids, alpha- or beta-adrenergic blockers or agonists, etc.)\n* smoking and illegal drug use\n* pregnant or lactating\n* gastrointestinal or bariatric surgery (except cholecystectomy and appendectomy)\n* individuals with electromedical devises\n* prisoners\n* alcohol abuse",{"count":176,"type":23},[58],"Time-restricted eating (TRE) is a dietary manipulation that involves restricting food intake to 6-12 h\u002Fday with no energy intake the rest of the day. In rodents, TRE improves metabolic function without caloric restriction, potentially by activating nutrient sensing mechanisms and effects on circadian oscillations. However, an understanding of the effect of TRE on cardiometabolic health in people is not clear and few studies have evaluated this issue. Accordingly, the investigators propose to conduct a randomized controlled trial in people with obesity and prediabetes to determine the effect of 9 h TRE for 12 weeks, without a change in body weight, on key metabolic outcomes that are risk factors for cardiovascular disease (CVD): 1) multi-organ insulin sensitivity; 2) 24 h metabolic homeostasis and diurnal rhythm; and 3) adipose tissue and skeletal muscle biology. The proposed studies will elucidate the cardiometabolic implications of TRE in people with obesity and prediabetes.",[29,31],{"date":550,"type":36},{"date":596,"type":36},"2023-11-01",{"date":598,"type":23},"2028-08-31",{"name":600,"class":43},"Cambridge University Hospitals NHS Foundation Trust",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":18,"minAge":298,"maxAge":124,"enrollmentInfo":609,"targetDuration":4,"studyType":56,"phases":611,"briefSummary":612,"conditions":613,"keywords":615,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":621,"completionDateStruct":622,"leadSponsor":624,"locationsCount":44},"100639574","personalized-meal-timing-and-walking-based-on-glucose-patterns-in-adults-with-prediabetes-100639574","NCT07618663","Personalized Meal Timing and Walking Based on Glucose Patterns in Adults With Prediabetes","CGM-Phenotyped Circadian Glycemic Vulnerability Windows to Personalize Meal Timing and Postprandial Activity in Prediabetes : A Randomized Controlled Trial","CLOCK-PRIME","Inclusion Criteria:\n\n* Age 30 to 70 years\n* Prediabetes, defined as either:\n* HbA1c 5.7% to 6.4% within 3 months of screening, or\n* Fasting plasma glucose 100 to 125 mg\u002FdL on two separate occasions\n* Body mass index 23 to 40 kg\u002Fm²\n* Owns a smartphone compatible with study applications\n* Willing to wear a continuous glucose monitor and wrist activity monitor during the study period\n* Willing to record meals using timestamped meal-photo logging\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Current or prior diagnosis of type 1 diabetes or type 2 diabetes\n* Use of glucose-lowering medication within the past 3 months\n* Use of systemic corticosteroid medication within the past 3 months\n* Use of prescription weight-loss medication within the past 3 months\n* Current shift work\n* Transmeridian travel across more than 2 time zones within 4 weeks before enrollment\n* Known untreated or unstable sleep disorder, including obstructive sleep apnea, narcolepsy, or insomnia disorder\n* Pregnancy, planned pregnancy, or breastfeeding\n* Gastrointestinal disease or surgery likely to affect nutrient absorption\n* Current participation in a structured dietary or exercise intervention program\n* Estimated glomerular filtration rate less than 60 mL\u002Fmin\u002F1.73 m²\n* Inability or unwillingness to comply with continuous glucose monitoring, wrist actigraphy, meal logging, or study visits",{"count":610,"type":23},105,[58],"This study will test whether glucose sensor data can be used to identify the time of day when adults with prediabetes are most likely to have high blood sugar after meals. Participants will first wear a continuous glucose monitor and wrist activity monitor and record meal times for 10 days. These data will be used to classify each participant's personal \"glycemic vulnerability window,\" such as morning, evening, or generally variable patterns.\n\nParticipants will then be randomly assigned to either personalized meal timing plus a short walk after their most vulnerable meal, or to an attention-matched control group receiving sleep hygiene and general step-count advice. The main outcome will be the change in post-meal glucose exposure during each participant's vulnerable window after 4 weeks.",[61,62,614],"Prediabetes or Diabetes",[61,181,616,617,618],"Precision Lifestyle Medicine","Meal Timing","Glycemic Variability","2026-05-24",{"date":516,"type":36},{"date":516,"type":23},{"date":623,"type":23},"2026-07-15",{"name":625,"class":43},"Shifa International Hospital",{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":4,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":18,"minAge":264,"maxAge":239,"enrollmentInfo":633,"targetDuration":4,"studyType":56,"phases":635,"briefSummary":636,"conditions":637,"keywords":638,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":646,"completionDateStruct":647,"leadSponsor":649,"locationsCount":44},"100611036","cardiometabolic-effects-of-pecan-snacking-in-prediabetes-100611036","NCT07235358","Cardiometabolic Effects of Pecan Snacking in Prediabetes","Glycemic Effects of Substituting Pecans for Snacks Higher in Saturated Fat and Added Sugars in Individuals With Prediabetes","Inclusion Criteria:\n\n* Age 25-65 years\n* Prediabetes assessed by an HbA1c of 5.7-6.4% at screening\n* BMI 25-40 kg\u002Fm2 at screening\n* Low habitual nut consumption (\\\u003C3.5 oz-eq\u002Fweek) assessed at the telephone screening\n* Regularly eats snacks higher in saturated fat and\u002For added sugars assessed at the telephone screening\n\nExclusion Criteria:\n\n* LDL-C ≥190 mg\u002FdL at screening\n* Hemoglobin \\\u003C13.2 g\u002FdL at screening\n* Fasting triglycerides \\>350 mg\u002FdL at screening\n* ≥10% change in body weight within the 6 months prior to enrollment\n* Blood pressure \\>140\u002F90 mmHg at screening\n* Type 1 or type 2 diabetes\n* Prescription of anti-hypertensive, lipid-lowering, or glucose-lowering drugs\n* Intake of supplements or over-the-counter medications that affect the outcomes of interest (i.e., lipid, blood pressure, or glucose lowering; vitamin C or multi-vitamins containing vitamin C) and are unwilling to cease during the study period.\n* History of liver, kidney, or autoimmune disease\n* Prior cardiovascular event (e.g., stroke, heart attack)\n* Current pregnancy or intention of pregnancy within the next 12 months\n* Lactation within the prior 6 months\n* Pecan allergy\u002Fintolerance\u002Fsensitivity\u002Fdislike\n* Unwilling\u002Funable to eat 1.5 oz of pecans every day as a snack during the duration of the study\n* Antibiotic use within the prior 4 weeks\n* Oral steroid use within the prior 4 weeks\n* Use of tobacco or nicotine-containing products within the past 6 months\n* History of cancer at any site within the past 10 years (eligible if ≥10 years without recurrence) or non-melanoma skin cancer within the past 5 years (eligible if ≥5 years without recurrence)\n* Participation in another clinical trial within 60 days of baseline\n* Unwilling to contact study staff before enrolling in other health-related research and avoid participating in any research that may interfere with this study.\n* Currently following a restricted or weight-loss diet\n* Prior bariatric surgery\n* Intake of \\>14 alcoholic drinks\u002Fweek and\u002For not willing to avoid alcohol consumption for 48 hours prior to test visits\n* Principal Investigator discretion related to the potential participant's ability to adhere to the study requirements, including being able to come to attend visits\n* Does not speak and\u002For understand English\n* Unwilling to refrain from donating blood or plasma during the study\n* Weight \\\u003C110 lb\n* If a potential participant takes thyroid medicine, abnormal thyroid stimulated hormone (TSH) concentration (TSH outside of normal range), or change in dose of thyroid medication within the last 6 months",{"count":634,"type":23},147,[58],"The purpose of this study is to investigate the effects of replacing snacks higher in saturated fats and added sugars with pecans on blood sugar control, heart health and diet quality in individuals with prediabetes. Participants will be randomized into one of two groups. Group 1 will consume 1.5 oz of pecans per day in place of normally consumed snacks higher in saturated fat and added sugars for 16 weeks. Group 2 will be asked to continue consuming their current diet for 16 weeks. Measures will be taken to evaluate blood sugar, heart health and dietary intake at the beginning and 16 weeks later.",[61],[639,640,641,642,278,643],"diet","nutrition","nuts","snacking","cardiovascular disease","2026-05-22",{"date":576,"type":36},{"date":644,"type":36},{"date":648,"type":23},"2027-09-30",{"name":650,"class":43},"Penn State University",{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":4,"eligibilityCriteria":657,"healthyVolunteers":17,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":658,"targetDuration":4,"studyType":56,"phases":660,"briefSummary":661,"conditions":662,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":666,"lastUpdatePostDateStruct":667,"startDateStruct":669,"completionDateStruct":671,"leadSponsor":673,"locationsCount":289},"100621600","smartwatch-based-intervention-for-cardiovascular-health-switch-100621600","NCT07372729","Smartwatch-based Intervention for Cardiovascular Health (SWITCH)","A Smart Wearable Devices-based Comprehensive Intervention Through a Cluster Randomized Controlled Trial to Improve Cardiovascular Health in Overweight\u002FObese Individuals With Cardiometabolic Preconditions","Inclusion Criteria:\n\n1. Age \\>= 18 years, no gender restriction;\n2. Overweight and obesity: Body Mass Index (BMI) 24.0-32.4 kg\u002Fm\\^2, or waist circumference \\>= 90 cm for males and \\>= 85 cm for females;\n3. Presence of at least one metabolic high-risk state among prehypertension, prediabetes, or borderline elevated blood lipids, and without a diagnosis of hypertension, diabetes mellitus, or dyslipidemia:\n\n(1) Prehypertension: Systolic blood pressure (SBP) 130-139 mmHg and\u002For diastolic blood pressure (DBP) 80-89 mmHg, without regular use of antihypertensive medication in the past month; (2) Prediabetes: Fasting blood glucose (FBG) 6.1-6.9 mmol\u002FL, or glycated hemoglobin (HbA1c) 5.7%-6.4%, without regular use of hypoglycemic medication in the past month; (3) Borderline elevated blood lipids: Total cholesterol (TC) 5.2-6.1 mmol\u002FL, or low-density lipoprotein cholesterol (LDL-C) 3.4-4.0 mmol\u002FL, or triglycerides (TG) 1.7-2.2 mmol\u002FL, or non-high-density lipoprotein cholesterol (non-HDL-C) 4.1-4.8 mmol\u002FL, without regular use of lipid-lowering medication in the past month; 4. Local permanent residents who will reside in the area for at least 12 month after enrollment; 5. Have basic reading, writing, and comprehension abilities; proficient in using internet-connected smartphones; able to independently complete basic operations of the application; 6. Written informed consent provided.\n\nExclusion Criteria:\n\n1. Secondary obesity diagnosed by doctors in secondary or higher-level medical institutions;\n2. Cardiovascular and cerebrovascular diseases, including myocardial infarction, stroke, heart failure, arrhythmia; or having received coronary intervention therapy, cardiac surgery, etc.; or with a 10-year high risk of cardiovascular disease;\n3. Diseases seriously affecting survival, such as malignant tumors, AIDS, hepatic and renal failure;\n4. Pregnancy, lactation period, or women who may become pregnant within one year;\n5. History of severe neuropsychiatric diseases with potential cognitive or communication impairments, such as dementia, Alzheimer's disease, Parkinson's syndrome;\n6. Individuals with limited daily mobility;\n7. Individuals undergoing or planning to receive weight loss through surgery, medication, or other methods;\n8. Currently participating in other lifestyle intervention-related trials.",{"count":659,"type":23},1400,[58],"This study aims to employ a cluster randomized controlled trial to evaluate the effectiveness of an mHealth-Based Multi-faceted Cardiovascular Health Intervention Model among Overweight\u002FObese Individuals with Cardiometabolic Preconditions, thereby providing theoretical foundations and practical guidance for the prevention and management of this population.",[663,664,665,61],"Prehypertension","Borderline Dyslipidemia","Overweight , Obesity","2026-05-12",{"date":668,"type":36},"2026-05-14",{"date":670,"type":36},"2026-03-24",{"date":672,"type":23},"2027-03-15",{"name":674,"class":43},"Beijing Anzhen Hospital"]